| Ytd | -10.00% | |
| 1y | -15.70% |
| Open | 6.36 | Prev Close | 6.32 | Low | 6.14 | High | 6.36 | Mkt Cap | 2.34B |
| Vol | 829.04K | Avg Vol | 3.52M | EPS | -2.94 | P/E | N/A | Forward P/E | 1.51 |
| Beta | 0.38 | Short Ratio | 1.77 | Inst. Own | 65.06% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | 11-10 | Earning | 10-28 | 50-d Avg | 5.52 | 200-d Avg | 5.85 | 1yr Est | 7.50 |
This year's Aspire Higher scholarships are awarded to six students who have been affected by dermato
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye
Bausch Health (BHC) shares have started gaining and might continue moving higher in the near term, a
Bausch (BHC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the compa
Bausch + Lomb is positioned as a turnaround and deleveraging opportunity, benefiting from a shift to
Paulson's hedge fund reduced its equity book to $2.58B in Q2, exiting two positions and opening
For the Seventh Consecutive Year, 10 Students with Gastrointestinal Disease Will Each Receive a $10
Bausch Health Companies Inc. has surged 40% post-Q2 on strong results and raised FY2026 guidance, bu
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further t
Investors were cheered by the beat-and-raise second quarter. The company also had good news to repor
LAVAL, QC, Aug. 6, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC) ("Bausch
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye
BHC beats Q2 estimates as Salix, Solta Medical and Bausch + Lomb fuel growth, lifting 2026 revenue a
Gainers Nuwellis (NASDAQ:NUWE) stock moved upwards by 123.7% to $4.23 during Thursday's regular
Bausch Health Companies Inc. (BHC) Q2 2026 Earnings Call Transcript
Bausch Health (BHC) came out with quarterly earnings of $1.26 per share, beating the Zacks Consensus
Bausch Health Cos NYSE: BHC reported second-quarter results that management said extended its streak
Although the revenue and EPS for Bausch (BHC) give a sense of how its business performed in the quar
Bausch Health Companies (TSX:BHC) raises FY2026 sales outlook from $10.670 billion-$10.920 billion t
Bausch Health Companies (TSX:BHC) reported quarterly earnings of $1.26 per share which beat the anal
Second Quarter Consolidated Revenues of $2.85 billion, up 13% on a Reported basis and 11% on an Orga
Bausch + Lomb said on Thursday its glaucoma eye drop had missed the main goal in a mid-stage trial
LAVAL, QC, July 7, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will releas
PrOKEDI® is a prolonged-release injectable suspension of risperidone indicated for the treatment of
LAVAL, QC, July 1, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today annou
Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), today announce
Thermage®, a pioneer in non-invasive skin tightening, was awarded the AAA Well-Known Trademark Certi
Bausch Health Companies (NYSE:BHC) raises FY2026 sales outlook from $10.625 billion-$10.875 billion
Bausch Health Companies (NYSE:BHC) reported quarterly earnings of $0.78 per share which beat the ana
RBC Capital analyst Douglas Miehm maintains Bausch Health Companies (NYSE:BHC) with a Sector Perf
Barclays analyst Glen Santangelo maintains Bausch Health Companies (NYSE:BHC) with a Equal-Weight
Bausch Health Companies (NYSE:BHC) sees FY2026 sales of $10.625 billion-$10.875 billion vs $10.595 b
Bausch Health Companies (NYSE:BHC) reported quarterly earnings of $1.10 per share which missed the a
https://ag.ny.gov/press-release/2026/attorney-general-james-secures-more-17-million-drug-manufacture
Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), today announced the results of the global Phase 3
Truist Securities analyst Les Sulewski maintains Bausch Health Companies (NYSE:BHC) with a Hold a
Barclays analyst Glen Santangelo initiates coverage on Bausch Health Companies (NYSE:BHC) with a
The Shibo group has served as Solta Medical's trusted distribution partner over the past decade.
Carl Icahn's empire, IEP, has collapsed 80% due to Hindenburg's short-selling attack. Icahn&
Bausch Health Companies (NYSE:BHC) reported quarterly earnings of $1.16 per share which beat the ana
Bausch Health Companies (NYSE:BHC) raises FY2025 sales outlook from $10.000 billion-$10.250 billion